Use of alternative and complementary medicine in menopause by Kang, H.J. et al.
International Journal of Gynecology and Obstetrics 79 (2002) 195–207
0020-7292/02/$ - see front matter  2002 International Federation of Gynecology and Obstetrics. Published by Elsevier Science
Ireland Ltd. All rights reserved.
PII: S0020-7292 Ž02 .00297-7
Review article
Use of alternative and complementary medicine in menopause
H.J. Kang , R. Ansbacher , M.M. Hammoud *a a b,
Division of Reproduction Endocrinology and Infertility, Department of Obstetrics and Gynecology,a
University of Michigan Medical School, Ann Arbor, MI, USA
Division of Women’s Health, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI,b
USA
Received 17 June 2002; received in revised form 12 September 2002; accepted 13 September 2002
Abstract
Objectives: To review the clinical evidence available for the treatment of menopausal symptoms with alternative
and complementary medicine. Methods: The MEDLINE, PREMEDLINE and COCHRANE electronic databases for
the years 1980–2002 were searched for articles concerning soy products, black cohosh, dong quai, acupuncture,
ginseng and evening primrose oil. Studies pertaining to menopausal vasomotor symptoms, lipid profiles and bone
mineral densities of postmenopausal women were included. The data from clinical trials were reviewed. Results: Soy
isoflavones slightly decrease total cholesterol and LDL levels. The clinical significance of this small change is yet to
be determined. The synthetic isoflavone derivative ipriflavone increases bone mineral density in healthy peri- and
postmenopausal women with moderate bone mineral densities. Although earlier reports have claimed that soy is
beneficial for the improvement of vasomotor symptoms, recent data do not support this claim. There are insufficient
data on the other alternative therapies for treating menopausal symptoms at this time. Conclusion: Alternative and
complementary medicine may play a role in the management of menopause, however, well-designed large studies are
still needed.
 2002 International Federation of Gynecology and Obstetrics. Published by Elsevier Science Ireland Ltd. All rights
reserved.
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1. Introduction
This is a time of unprecedented growth in the
popularity of alternative and complementary med-
icines for the management of the symptoms of
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menopause. Forty percent of Americans reported
using alternative therapies to treat medical condi-
tions in 1997 w1x. Menopausal women account for
one of the largest segments of alternative medicine
users, with 80% of women aged 45–60 reporting
the use of non-prescription therapies for the man-
agement of menopausal symptoms w2x. These ther-
apies include herbal remedies, meditation,
traditional Chinese medicine, vitamins and miner-
als, homeopathy, acupuncture and chiropractic
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practices w3x. Women cite a large number of
reasons for their interest in these therapies. They
are perceived to be safer than hormone replace-
ment therapy, and some women report feeling that
they are taking more personal control over their
health care by using alternative therapies w4x. Other
reasons women cite against hormone replacement
therapy include fear of cancer, dislike of side
effects such as vaginal bleeding, and the view that
the menopause is a natural transition w5x.
The regulation of alternative therapies has not
kept pace with the fast growth of the industry. The
1994 Dietary Supplement Health and Education
Act (DSHEA) stated that dietary supplements,
including herbs and vitamins, would not be con-
sidered foods, and therefore would no longer
require a pre-market safety evaluation w6x. This
regulation was passed in response to both consum-
er and manufacturer demand. Large discrepancies
have been found between label content and the
actual active ingredients found in many of these
dietary supplements after the passage of the
DSHEA. Some herbal supplements have even been
found to contain unreported contaminants w7x. A
study by the Food and Drug branch of the Cali-
fornia Department of Health Services found that
32% of Asian patent medicines contained undecla-
red pharmaceuticals or heavy metals w8x. In addi-
tion, claims of dietary supplements do not have to
adhere to rigorous clinical standards.
There is a dichotomy between the vast amount
of alternative medicine lay literature that women
may be reading and the lack of clinical evidence
available for physicians on these same topics.
Randomized, placebo-controlled clinical trials are
just beginning to be performed on just a few of
the major, non-traditional therapies, with very little
clinical information available on the vast majority
of alternative dietary supplements. This paper will
discuss the alternative therapies associated with
the treatment and management of menopausal
symptoms, and will present and analyze the most
recently published clinical information pertaining
to these alternative therapies. The clinical data are
classified and presented by menopausal symptom
category.
2. Alternative therapies
2.1. Soy products
Derived largely from soy products, phytoestro-
gens are currently the most popular alternative to
hormone replacement therapy w9x. They are plant-
derived compounds that are structurally and func-
tionally similar to estradiol w10x. Isoflavones are
one class of phytoestrogens. Genistein and daid-
zein are the two major types of isoflavones. They
are found in soy, clover, lentils, beans and chick-
peas. In humans, gastrointestinal tract enzymes
convert isoflavones into heterocyclic phenols that
have a structural similarity to estrogen w11x. The
beneficial effects of soy supplements in postmen-
opausal women have been attributed to these
isoflavones.
Isoflavones appear to be selective estrogen
receptor modulators with modest agonist activity
at the beta estrogen receptor, at approximately one-
third the potency of estradiol. They also appear to
have very weak alpha estrogen receptor activity,
with 0.001 the potency of estradiol w12x. The
relative expression of alpha and beta estrogen
receptors varies between tissues in the body. Iso-
flavones appear to have both estrogenic and anti-
estrogenic behavior w13x.
2.2. Black cohosh
Black cohosh (Cimicifuga racemosa) is an
indigenous Eastern North American plant that has
been used by Native Americans for gynecological
conditions since before the arrival of European
settlers to North America. Called ‘squaw root’
because it was used primarily for female disorders,
it was first listed in the Pharmacopoeia of the
United States in 1830 under the name ‘black
snakeroot.’ It was the primary ingredient of Lydia
Pinkham’s tonic compound for ‘female com-
plaints,’ which sold widely for more than 50 years
in the early twentieth century w14x. In 1989, the
German Commission E, an expert panel commis-
sioned by the German government to address
herbal products, approved black cohosh as a non-
prescription medicine for the treatment of climac-
teric ailments. The commission recommended,
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however, that black cohosh be used for no longer
than 6 months due to an uncertainty about its
possible long-term side effects w15x. The treatment
of menopausal signs and symptoms has been the
primary therapeutic application of black cohosh. It
is the main ingredient in the often-used over-the-
counter menopausal preparation ‘Remifemin’
(Schaper Brummer, Germany, distributed by
PhytoPharmica, Green Bay, WI).
The mechanism by which black cohosh may
exert its effects is unclear. It was once believed
that it may have estrogen-like activity, but the
results of various studies have been varied. One
study reports that black cohosh binds competitively
to the beta estrogen receptor w16x, but studies by
Remifemin’s manufacturer report that it does not
perform as a true estrogen w17x. The biologically
active component of black cohosh is attributed to
a number of triterpene glycosides. Remifemin is
standardized in respect to triterpene glycoside
content.
2.3. Dong quai
Dong quai is an herb native to Eastern Asia and
China. It has been used for more than 1000 years
as a spice, tonic and medicine in traditional Chi-
nese medicine. Dong quai is known as the ‘female
ginseng’ and is currently the second best-selling
herb in China w18x. It is indicated for dysmenor-
rhea, irregular menstruation and as a supportive
herb for menopausal complaints w19x. In the West,
dong quai has become popular as an herb for
treating menopausal symptoms.
Dong quai was one of the first alternative
therapies to which potentially adverse effects were
attributed, for it potentates the effects of warfarin.
Dong quai contains furocoumatins, which are cou-
marin-like substances that act as anticoagulants
w20x.
2.4. Acupuncture
Acupuncture is another component of Chinese
medicine that dates back at least 2500 years. The
term ‘acupuncture’ describes a number of different
practices that involve puncturing the body (as with
thin needles) at specific points to cure disease or
relieve pain. The mechanism of action is thought
to involve the release of opioid peptides at the
acupuncture sites. There may also be activation of
the hypothalamus and the pituitary gland, causing
a broad spectrum of systemic effects w21x. The
benefits of acupuncture are being evaluated for a
vast array of health conditions from post-chemo-
therapy nausea and vomiting, to menstrual cramps,
stroke rehabilitation and the symptoms of
menopause.
2.5. Ginseng
The word ‘ginseng’ is derived from ‘panacea,’
meaning cure-all. It is said to boost immunity,
energy and vigor, and has been reported to have
estrogenic properties. There have been a number
of studies reported by Consumer Reports, the Los
Angeles Times and Consumerlab.com that have
criticized the production quality of ginseng prod-
ucts. One study reported that only 25% of the
commercially available products actually contained
ginseng w22x. Large quantities of caffeine have
also been found in many ginseng products w23x.
2.6. Evening primrose oil
Evening primrose oil comes from the seeds of
the yellow primrose, a North American wildflower.
It has a long history of use by Native Americans.
The seeds contain oils rich in linolenic acid and
g-linolenic acid, precursors of prostaglandin E.
Disorders for which evening primrose oil have
been tested include atopic dermatitis, rheumatoid
arthritis, mastalgia, breast cysts, premenstrual syn-
drome and menopausal hot flashes w24x.
3. Methods
The MEDLINE, PREMEDLINE and COCH-
RANE databases from January 1, 1980 through
April 9, 2002 were searched for articles using the
keywords ‘alternative medicine,’ ‘phytoestrogens,’
‘isoflavones,’ ‘soy,’ ‘black cohosh,’ ‘dong quai,’
‘ginseng,’ ‘evening primrose oil’ and ‘acupunc-
ture,’ and cross-referenced with the terms ‘meno-
pause,’ ‘hot flashes,’ ‘night sweats,’ ‘coronary
disease,’ ‘hyperlipidemia,’ ‘bone mineral density’
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and ‘osteoporosis.’ The reference lists of published
articles and abstracts were searched for relevant
articles that were not found in the database search-
es. Lay literature concerning alternative medicine
use was obtained through Internet searches. Crite-
ria for the selection of articles for analysis included
human subjects and appeared in the English lan-
guage. This review only considers evidence from
clinical trials and randomized controlled studies
performed from 1996 to 2002.
4. Results
Although a large amount of medical literature
is available on alternative therapies, very little of
this literature contains clinical data from well-
conducted studies. The majority of the clinical data
that is available is on the soy isoflavones, with a
small amount of clinical data available on black
cohosh, dong quai, acupuncture, ginseng and eve-
ning primrose oil.
4.1. Hot flashes
Hot flashes and night sweats are the most
common manifestations of the climacteric in the
United States. They often occur in the perimeno-
pausal and early menopausal phase, with up to
75% of women experiencing varying degrees of
these symptoms w25x. The majority of women do
not consider these vasomotor symptoms to be
overly unpleasant, and only approximately one-
fifth find them distressing enough to seek medical
assistance w26x. Hormone replacement therapy
(HRT) is currently recognized as the most effec-
tive treatment for the short-term symptoms of
menopause. One study found that there was a 77%
reduction in the frequency of hot flashes, and that
symptom severity was also significantly reduced
in HRT users as compared to the placebo w27x.
The hypothesis that soy isoflavones may exert
pro-estrogenic effects on menopausal symptoms
originated in part from epidemiological observa-
tions that hot flash occurrence is much lower in
Asian countries than in Western countries. Less
than 25% of Japanese women report experiencing
hot flashes w28x. It is estimated that the Japanese
consume 200 mg of phytoestrogens per day, 50
mg of which are isoflavones w29x. Some research-
ers maintain that the high dietary intake of phy-
toestrogens may explain why Japanese women
experience fewer hot flashes than their Western
counterparts. A 2001 cohort study of Japanese
women revealed an inverse relationship between
soy product intake and hot flashes w30x.
Although a large number of clinical trials have
reported a decrease in hot flashes in women treated
with soy protein, many of these trials did not prove
that soy was superior to the placebo. Five clinical
studies demonstrated no statistical difference
between soy treatment and placebo groups (see
Table 1) w31–35x. The placebo effect in these
studies was quite high, with hot flash reduction
values in the placebo groups ranging from 20 to
25%. The St. Germaine study commented on the
strong placebo effect, noting that greater than 50%
of the women participating in their trial stated at
the conclusion of the trial that they believed they
were in the high isoflavone treatment group. Only
one-third of the women were actually in the
treatment group w35x.
However, two clinical trials have reported a
significant decrease in hot flashes in the group
treated with soy product over the placebo w36,37x.
Hot flash frequency was reduced by 45% and
28%, respectively, in these trials. The placebo
effect was high in both of these studies, with
values of 30% and 18%. The dose and method of
administration necessary to produce symptom
improvements remains unclear at this time. The
trials performed thus far have utilized 50–150 mg
of isoflavone with conflicting results, with no
apparent relationship between isoflavone dose and
symptom relief.
Other herbal supplements have been reported in
the lay literature to relieve vasomotor symptoms
in menopausal women. One clinical trial examined
dong quai vs. placebo in postmenopausal women.
Both the treatment group and the placebo group
experienced a benefit in terms of reduced number
and intensity of hot flashes, with no statistical
difference between the two treatment arms. The
authors did note that treatment with dong quai
alone can be criticized because Chinese practition-
ers never prescribe the herb alone, but rather
typically use it in conjunction with other herbs.
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Table 1
Hot flashes
Author Design Intervention Subjects Results
Knight et al., 2001 w31x Double-blind, Powder containing 134.4 mg 24 womena No improvement in HF
randomized, placebo- of isoflavones )3 HFyday over placebo
controlled trial
Murkies et al., 1995 w32x Double-blind, Soy flour 58 womena HF decreased 40% in
randomized, placebo- )14 HFyweek soy flour group
controlled trial
Brzezinski et al. 1997 w33x Double-blind, Phytoestrogen-rich diet 145 womenb No improvement in HF
randomized, placebo- over placebo
controlled trial
Quella et al., 2000 w34x Double-blind, Soy tablets containing 177 breast cancer survivors No improvement in HF
randomized, parallel, 50 mg soy isoflavone with HF over placebo
placebo-controlled trial
St. Germain et al., 2001 w35x Double-blind, 80.4 mg isoflavone, vs. 69 women )10c No improvement in HF
randomized, placebo- 4.4 mg isoflavone HFyday over placebo
controlled trial
Albertazzi et al., 1998 w36x Double-blind, parallel, Soy protein containing 104 women )7a HF statistically improved
randomized, placebo- 76 mg of isoflavone HFyday in soy group
controlled trial
Upmalis et al., 2000 w37x Double-blind, Soy isoflavone extract 177 women )5a HF statistically improved
parallel, placebo- containing 50 mg genistein, HFyday in treatment group
controlled trial 50 mg daidzen
Hirata et al., 1997 w38x Double-blind, Dong quai 71 womena No improvement in HF
randomized, placebo- over placebo
controlled trial
Wiklund et al., 1999 w39x Double-blind, Ginseng 384 womena No improvement in HF
randomized, parallel over placebo
group trial
Davis et al., 2001 w40x Double-blind, Chinese medicinal herbs 55 women )14a No improvement in HF
randomized, placebo- HFyday over placebo
controlled trial
Jacobson et al., 2001 w41x Double-blind, Black cohosh 85 women with breast No improvement in HF
randomized, placebo- cancer over placebo
controlled trial
Chenoy et al., 1994 w42x Double-blind, Evening primrose oil 56 women )3d No improvement in HF
randomized, placebo- 1000 mg HFyday over placebo
controlled trial
Wyon et al., 1994 w43x Randomized, placebo- Electrostimulated 24 womend Number of hot flashes
controlled trial acupuncture vs. superf remained consistently
needle position acupuncture decreased in acupuncture
group
Kraft et al., 1999 w44x Randomized, single- Acupuncture 10 womena Significant reductions in
blind placebo- menopausal complaints
controlled trial
Postmenopausal.a
Peri- and postmenopausal.b
Perimenopausal.c
Menopausal.d
However, one study found that women in the
United States typically take dong quai alone as a
single entity w38x. A study performed by the
Ginsana Corporation, the largest manufacturer of
ginseng products worldwide, also reported no
improvement in hot flashes over the placebo w39x.
An Australian study examined whether a defined
formula of Chinese medicinal herbs could relieve
menopausal symptoms. The authors state that the
Chinese medicinal herbs were comprised of a
modified traditional formula of herbs, and listed
the 12 herbs contained in the formula, but did not
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give further information about their choice of
selection of herbs for this formula. Again, there
was no significant or clinically relevant difference
in the frequency of vasomotor symptoms between
placebo and Chinese medicinal herb therapy, with
both groups experiencing a statistically significant
decline in symptoms w40x.
A clinical trial published in 2001 that studied
the effects of black cohosh on breast cancer
patients who experienced hot flashes also showed
no difference between treatment groups and the
placebo. The authors’ state that they believe that
the patients’ feeling of security from taking a
medication believed to control hot flashes could
have reinforced the tendency for the positive pla-
cebo response in participants w41x. Another trial
performed on evening primrose oil showed that
there was no statistical difference in the relief of
vasomotor symptoms between the treatment group
and the placebo group w42x.
Although not many studies have examined the
effects of acupuncture on hot flashes, two Euro-
pean studies have reported promising findings. A
Swedish study examined the effects of electrosti-
mulated acupuncture and superficial needle posi-
tion acupuncture on hot flashes. It found that
patients benefited from the electrostimulated acu-
puncture, and not from the placebo superficial
needle position acupuncture w43x. A German study
published in 1999 reported a decrease in meno-
pausal complaints after acupuncture therapy vs. a
placebo w44x.
There is still a paucity of clinical data on these
various alternative therapies for the treatment of
menopausal symptoms. A greater number of ran-
domized controlled clinical trials need to be per-
formed on black cohosh, dong quai, evening
primrose oil and acupuncture for the treatment of
menopausal symptoms.
4.2. Bone mineral density
Osteoporosis has become a very important
health issue, with more than 23% of women over
65 years old having osteoporosis w45x. The primary
cause is currently thought to be a decrease in
endogenous estrogens at menopause. HRT and
bisphosphonates are currently accepted to be the
best pharmaceutical method to maintain bone min-
eral density in postmenopausal women w46x.
Ipriflavone is a synthetic isoflavone that has
been reported to reduce the rate of bone loss in
postmenopausal women. This drug is produced
commercially from the isoflavone daidzen. It
became evident from the earliest studies that ipri-
flavone was effective in increasing the calcium
content of skeletal tissue in animals w47x. Early
studies also reported that ipriflavone may be as
effective as estrogen in its ability to prevent bone
loss, and a combination of the two treatments was
complementary w48x. Ipriflavone is reported to
work by inhibiting osteoclast activity and stimu-
lating osteoblast activity w49x.
A three-year study performed by the Ipriflavone
Multicenter European Fracture Study reported that
ipriflavone had no beneficial effect over the pla-
cebo. The authors note that their participants could
have had too little initial bone mass to benefit
from treatment (see Table 2) w50x. This study
reported conflicting results as compared to four
other clinical trials performed on women with
osteoporosis or osteopenia, which have mostly
reported the beneficial effects of ipriflavone on
bone mineral density. Ipriflavone effectiveness has
been measured by bone mineral density measure-
ments, urinary bone resorption marker detection
and biochemical markers of bone resorption w51–
54x. In the study by Halpner et al., the subjects on
the treatment arm received a dietary supplement
containing vitamin D and calcium, as well as the
ipriflavone. There was no explanation given for
the contents of the placebo supplement, and one
can infer that the placebo may not have contained
the vitamin D and calcium. Therefore, the
decreased rates of urinary bone resorption markers
may not have been purely due to the ipriflavone,
but rather may have been due to the combined
effect of the other components in the supplement.
Although there are some conflicting data from the
clinical trials performed on ipriflavone, it appears
that it does have at least some effect on decreasing
bone turnover and maintaining bone mineral den-
sity. Additional research is needed to further char-
acterize which menopausal women would benefit
from this treatment, and the clinical significance
of the magnitude of benefit in decreasing fractures.
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Table 2
Bone mineral density
Authors Design Intervention Subjects Outcome measures Results
Alexandersen et al., 2001 w51x Randomized, double- Ipriflavone 600 mg 292 womena Spine, hip, forearm BMD, No difference in BMD
blind placebo-controlled with osteoporosis biochemical markers of
trial, 3 years bone resorption
Agnusdei et al., 1997 w52x Randomized, double- Ipriflavone 600 mg 198 womena L2–L4 vertebral BMD, Significant increase in vertebral
blind, placebo- with BMD 1 S.D. biochemical markers of BMD in treatment group
controlled, parallel group below normal bone resorption
study, 2 years
Adami et al., 1997 w53x Randomized, Ipriflavone, 600 mg 250 womena Radial BMD, biochemical Radial BMD decreased in
prospective, double- with BMD 1 S.D. markers of bone placebo, maintained BMD in
blind, parallel group below mean resorption treatment group
trial, 2 years
Gennari et al., 1998 w54x Randomized, placebo- Ipriflavone 600 mg 56 womena BMD, urine BMD decreased in placebo,
controlled trial with low BMD hydoxyprolineycreatinine no change in BMD in
treatment group
Halpner et al., 2000 w55x Placebo-controlled trial 300 mg ipriflavone, 7 healthy Urinary N-linked N-linked telopeptide declined
Vit D, Ca dietary womena telopeptide levels 29% in patients receiving
supplement supplement
Bassey et al., 2000 w56x Randomized, placebo- Efacal (1.0 g Ca, 4.0 43 womenb BMD, biochemical No significant difference
controlled trial, 1 year g evening primrose 42 womena markers of bone between treatment and placebo
oil) vs. 1.0 g Ca resorption
Kruger et al., 1998 w57x Randomized, placebo- g linolenic acid and 65 womena BMD, biochemical Significant increase in lumbar
controlled, 18 months eicosapentaenoic with osteoporosis markers of bone and femoral BMD in
acid resorption treatment group
Postmenopausal.a
Premenopausal.b
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A small number of clinical studies have explored
the effects of evening primrose oil on bone mineral
density. A study of the dietary supplement Efacal
(Efamol Nutraceuticals Inc, Boston, MA), which
contains 1.0 g of calcium, 4.0 g of evening
primrose oil and 440 mg of marine fish oil, found
no difference in bone mineral density or bone
turnover markers in premenopausal and postmen-
opausal women in the treatment arm of the study.
The authors conclude that Efacal has no effect on
bone mineral density in women w55x. When the g-
linolenic acid component of evening primrose oil
was separately tested, bone mineral densities
increased in the treatment groups, and decreased
in placebo groups w56x. More studies need to be
performed to clarify whether evening primrose oil
is helpful in delaying bone mineral density loss in
postmenopausal women.
4.3. Lipid profiles
The relationship between soy products and lipid
profiles has been investigated for many years.
Animal studies as early as the 1940s demonstrated
the beneficial effect of soy proteins on lipid pro-
files w57x. Recent animal studies also demonstrated
the benefits of soy isoflavones on total cholesterol
and LDL w58x. In addition, various cross-sectional
analyses demonstrated an inverse relationship
between soy intake and cholesterol levels w59,60x.
A meta analysis of 38 clinical trials that exam-
ined the relationship between soy protein intake
and serum lipids report that the consumption of
soy in men and women is associated with a
significant decrease in serum cholesterol, LDL and
triglyceride levels. This association was strongest
for subjects with higher initial levels of cholesterol.
In 34 out of the 38 studies, serum cholesterol
levels decreased in treatment subjects following
the consumption of soy. The four trials that found
no effect from the consumption of soy consisted
of women with fairly low initial cholesterol levels.
The authors of this meta analysis report that an
average intake of 47 g of soy protein per day
resulted in statistically significant reductions in
total cholesterol, LDL and triglyceride levels w61x.
A recently published randomized controlled
cross-over trial examined the effects of isoflavone
in 18 postmenopausal women with either normal
or mildly elevated cholesterol levels. LDL was
found to be 6.5% lower in the high-isoflavone
treatment group, and was also significantly lower
in the low isoflavone treatment group. The LDLy
HDL ratio was also lower in the isoflavone treat-
ment groups, although the low dose isoflavone
group actually had lower values than the high
isoflavone group (see Table 3) w62x. A study that
tested soy protein on patients with moderately
elevated cholesterol levels reported similar lipid-
lowering results w63x. Another study that was
performed on perimenopausal women with normal
lipid profiles reported similar lipid lowering results
w64x. A randomized, double blind placebo-con-
trolled trial examined the effects of dietary soy
supplements containing 118 mg isoflavones on the
lipid profiles of men and postmenopausal women
with relatively normal cholesterol levels. The
LDLyHDL ratio was again decreased in the isofla-
vone treatment groups, but there was no reported
change in total cholesterol w65x.
The mechanism by which soy isoflavones are
thought to alter lipid profiles remains unknown,
but a study that examined the effects of 56 mg
and 90 mg of isoflavones on hypercholesterolemic
postmenopausal women reported increased HDL
cholesterol and increased messenger RNA levels
in the isoflavone treatment groups. The authors
proposed that soy protein may improve lipid pro-
files by altering LDL receptor quantity or quality
w66x. When markers of lipid peroxidation and
resistance of LDL to oxidation were examined in
men and women treated with isoflavone vs. pla-
cebo, researchers found a reduced lipid peroxida-
tion in vivo, and increased resistance of LDL to
oxidation. LDL oxidation is considered to be a
prerequisite for the uptake of LDL by macrophages
in the artery wall, an early step in the formation
of atheroma. The authors concluded that the anti-
oxidant action of soy isoflavones could be signif-
icant in reducing cardiovascular disease risk and
atherosclerosis w67x. Other mechanisms that have
been proposed for the hypocholesterolemic effect
of soy include enhancement of bile acid excretion,
increased hepatic metabolism of cholesterol, and
altered variations in hormone secretion w68x.
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Table 3
Lipid profiles
Author Design Intervention Subjects Outcome measures Results
Wangen et al., 2001 w63x Randomized, cross-over 65 mg isoflavone vs. 18 women ,a TC, LDL, HDL, Apo A-1, Significantly decreased LDL,
trial, 93 days 132 mg isoflavones with normal or mildly apo B, TG LDLyHDL ration in 132 mg
elevated cholesterols isoflavone group
Crouse et al., 1999 w64x Randomized, double- Soy protein containing 3, 38 women,a TC, LDL, HDL, TG TC and LDL decreased in high
blind parallel trial, 27, 37, 62 mg isoflavones 24 women,b isoflavone treatment groups
9 weeks 94 men, moderately
elevated cholesterol
Washburn et al., 1999 w65x Randomized, double- 34 mg phytoestrogen 51 healthy women TC LDL, HDL, TG 6% lower TC, 7% lower LDL in
blind, cross-over trial, soy treatment groups
6 weeks
Teede et al., 2001 w66x Randomized, placebo- Dietary soy supplements 96 men, 83 TC, LDL, HDL, TG, Decreased TG, LDLyHDL ratio,
controlled, double-blind containing 118 mg women witha lipoprotein A increased lipoprotein A in
3 months trial isoflavones normal cholesterol treatment group
Baum et al., 1998 w67x Parallel group, double- Soy protein with 56 mg 66 womena TC, LDL, HDL, LDL mRNA increased in
blind trial isoflavone vs. 90 mg with high receptor mRNA isoflavone groups
isoflavone cholesterols
Wiseman et al., 2000 w68x Randomized, cross- Soy protein high in 19 women, 5 men 8-epi-PGF2a, F2 8-epi-PGF2a levels were lower,
over trial isoflavone isoprostane, resistance of LDL oxidation lag time was
LDL to oxidation longer in high isoflavone groups
Howes et al., 2000 w70x Randomized, double- Isoflavone extract containing 75 womena TC, LDL, HDL, TG. Treatment group showed no
blind increasing dose 26 mg biochanin A, 16 mg with moderately change in total cholesterol, LDL,
placebo-controlled trial, formononetin, 0.5 mg elevated cholesterol HDL or TG
10 weeks genistein, 1 mg daidzein
from red clover
Hodgson et al., 1998 w71x Randomized, double- Tablet containing 55 mg 46 men, 13 Total chol, LDL, HDL, No change in any of the lipid
blind, placebo-controlled isoflavone women witha triglycerides, lipoprotein parameters
parallel group design average serum lipid
8 weeks profiles
Ishikawa et al., 1989 w75x Placebo-controlled, Evening primrose oil 19 patients with high LDL, apolipoprotein B LDL, apolipoprotein B levels
cross-over design, cholesterols decreased in treatment group
116 weeks
TC, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, triglycerides.
Postmenopausal.a
Premenopausal.b
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Some studies report no change in lipid profiles
from the ingestion of isoflavone. When isoflavone
extract from red clover was administered to post-
menopausal women with moderately elevated cho-
lesterol levels, the treatment groups showed no
change in LDL, HDL, triglyceride or total choles-
terol levels. The authors maintain that although
they used the red clover isoflavones biochanin A
and formonetin, these compounds are metabolized
in vivo to genistein and daidzein, respectively
w69x. When isoflavone was administered in a tablet
form to men and women with average lipid pro-
files, no change was reported in any of the lipid
parameters w70x. This study may have conflicting
results due to the lower lipid profile levels of its
participants, for soy isoflavones appear to be most
beneficial for patients with elevated lipid profile
levels. Overall it appears that soy protein isofla-
vones are able to play a role in reducing cardio-
vascular risk factors in at least some patients. It
also appears that the beneficial effects are greatest
in subjects with initially elevated lipid profile
levels.
Several animal studies report a beneficial effect
of evening primrose oil on hyperlipidemia w71–
73x. A clinical trial performed in the early 1980s
reports that evening primrose oil was effective in
lowering LDL levels and apolipoprotein B levels
in hypercholesterolemic men and women w74x.
5. Discussion
The explosion of public interest in alternative
and complementary therapies for the treatment of
menopausal symptoms will continue to grow and
expand in the years ahead. The medical literature
examining these therapies needs to grow as well
for there is too little clinical evidence currently
available. As the number of studies increases,
better evidence will become available. At this time,
soy isoflavones do not offer benefits superior to
placebo in the alleviation of hot flashes. However,
there does appear to be a lipid-lowering benefit to
soy isoflavones, with the greatest benefit occurring
in women with elevated initial lipid levels. In
terms of osteoporosis prevention, the synthetic
isoflavone ipriflavone may prove to be beneficial
in preserving bone mineral density in postmeno-
pausal women with higher initial bone mineral
densities.
There is a great paucity of literature regarding
black cohosh. Most clinical trials have been per-
formed in Germany, with a large proportion of the
studies having been performed by the Remifemin
manufacturer. At this point, the only English study
has been performed on breast cancer survivors
experiencing hot flashes. This trial reports no
decrease in hot flashes in participants taking black
cohosh over placebo, but it must be noted that a
number of the patients were taking tamoxifen at
the time of the study.
Although dong quai is not as well known or
popular in the United States, it is of great impor-
tance since it has been found to have anticoagulant
properties. Seventy percent of Americans who use
alternative medicines report not discussing these
therapies with their physicians w75x. Therefore it
is critical that caregivers try to open a dialogue
with their patients on this subject.
Despite the vast amount of lay literature regard-
ing alternative therapies for relieving menopausal
symptoms, there have been very few clinical trials
performed on them. Ginseng, acupuncture and
evening primrose oil have all been reported to
decrease menopausal symptoms. However, there
are insufficient data at this time to make any
conclusions on their potential efficacy and safety
for the treatment of symptoms in menopausal
women.
Public interest in complementary and alternative
therapies for the relief of menopausal symptoms
continues to increase as many baby boomers are
at this stage in life. Because of the 1994 Dietary
Health and Education Act (DSHEA), there is
currently no surveillance of safety or efficacy of
nutritional supplements. Women are conducting
uncontrolled trial on themselves when they take
these compounds. This makes it more necessary
for the clinical knowledge to continue to grow so
that physicians will be able to better discuss and
advise their patients on these topics.
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